Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUMO2 | P61956 | 1/20 | 0.57 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.57 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14988339 | 1.00 | SUMO2 (0.57) | SUMO2SUMO1SENP7SENP2SENP1 | |
| SCHEMBL29697057 | 0.99 | SUMO2 (0.58) | SUMO2SUMO1SENP7SENP2SENP1 | |
| SCHEMBL15120163 | 0.99 | SUMO2 (0.58) | SUMO2SUMO1SENP7SENP2SENP1 | |
| SCHEMBL18044206 | 0.99 | SUMO2 (0.58) | SUMO2SUMO1SENP7SENP2SENP1 | |
| SCHEMBL14988740 | 0.90 | — | — | |
| SCHEMBL14988743 | 0.90 | — | — | |
| SCHEMBL14988276 | 0.89 | — | — | |
| SCHEMBL14988280 | 0.89 | — | — | |
| SCHEMBL14988318 | 0.89 | SLC7A11 (0.66) | SUMO2SUMO1SENP7SENP2SENP1 | |
| SCHEMBL14988313 | 0.89 | SLC7A11 (0.66) | SUMO2SUMO1SENP7SENP2SENP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | claimed |
| EP-3042658-B1 | MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE | UNIV KYOTO (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-2959903-B1 | MEDICINE FOR TREATING EYE DISEASE | UNIV KYOTO (JP) | 2018-10-03 | — | — | EP | disclosed |
| US-9931351-B2 | Method for improving leptin resistance | KYOTO UNIVERSITY (JP) | 2018-04-03 | — | — | US | disclosed |
| US-9782420-B2 | Method for treating eye diseases | KYOTO UNIVERSITY (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9573887-B2 | Naphthalene derivative | DAITO CHEMIX CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160303144-A1 | Medicinal Composition Improving Leptin Resistance | KYOTO UNIVERSITY (JP) | 2016-10-20 | — | — | US | disclosed |
| EP-2599771-B1 | NAPHTHALENE DERIVATIVE | DAITO CHEMIX CORP (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3042658-A1 | MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE | Kyoto University (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160000810-A1 | Method For Treating Eye Diseases | KYOTO UNIVERSITY (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2959903-A1 | MEDICINE FOR TREATING EYE DISEASE | Kyoto University (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2623494-B1 | AGENT FOR TREATMENT OF EYE DISEASES | DAITO CHEMIX CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | KYOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2623494-A1 | AGENT FOR TREATMENT OF EYE DISEASES | Daito Chemix Corporation (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000810-A1 | Method For Treating Eye Diseases | CFB, AGER, CFH | SUMO2 3428/4885SUMO1 3027/4885SENP7 2564/4885 |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | PDE6A, ALDH1A2, PDE6D | SUMO2 3028/4885SUMO1 3509/4885SENP7 3222/4885 |
| US-20160303144-A1 | Medicinal Composition Improving Leptin Resistance | LIPC, ADIPOR1, GPR119 | SUMO2 4540/4885SUMO1 4341/4885SENP7 2517/4885 |
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | SUMO2 1084/4885SUMO1 955/4885SENP7 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.